Thus, PIM1 kinase activity may contribute to sustained disease severity, as evidenced by the successful use of a PIM1 inhibitor as a therapeutic measure in an IBD model mediated by CD4+ T cells (93). The gene discussed is CD4; the disease is inflammatory bowel disease.